Mechanism
Retatrutide is a triagonist of GLP-1, GIP, and glucagon receptors, classified within the tri-receptor activation pathway. Structurally it is a 39-residue triagonist with γGlu-C20 lipid modification. Coskun et al. (2022) and Jastreboff et al. (2023) characterized retatrutide as the first clinically validated triple agonist of the GLP-1, GIP, and glucagon receptors. Its combined receptor activity drives a distinct downstream signaling profile relative to dual or mono-agonists.
In an in-vitro setting, Retatrutide interacts with its target receptor(s) at low-nanomolar affinities under standard binding-assay conditions. Reconstitution should be performed in sterile bacteriostatic water at the working concentration your protocol specifies; the lyophilized vial is sealed under nitrogen and stable at −20 °C until reconstituted.
Common research applications
- In-vitro receptor-binding and dose-response screens against the tri-receptor activation target panel.
- Comparative pharmacology against related class members and previously published reference standards.
- Time-course studies leveraging Retatrutide's known stability profile.
- Cross-batch HPLC fingerprint comparison against the lot-specific COA we publish for every release.
Storage & handling
Retatrutide arrives lyophilized at −20 °C in cold-chain insulated packaging. On receipt, transfer immediately to a −20 °C freezer. Once reconstituted, store at 2-8 °C and use within the window noted on the lot's COA. Avoid repeated freeze-thaw cycles.
